TY - JOUR
T1 - Modeling breast cancer-associated c-Src and EGFR overexpression in human MECs
T2 - C-Src and EGFR cooperatively promote aberrant three-dimensional acinar structure and invasive behavior
AU - Dimri, Manjari
AU - Naramura, Mayumi
AU - Duan, Lei
AU - Chen, Jing
AU - Ortega-Cava, Cesar
AU - Chen, Gengsheng
AU - Goswami, Rasna
AU - Fernandes, Norvin
AU - Gao, Qingshen
AU - Dimri, Goberdhan P.
AU - Band, Vimla
AU - Band, Hamid
PY - 2007/5/1
Y1 - 2007/5/1
N2 - Epidermal growth factor receptor (EGFR), a member of the ErbB family of receptor tyrosine kinases, is overexpressed in as many as 60% cases of breast and other cancers. EGFR overexpression is a characteristic of highly aggressive molecular subtypes of breast cancer with basal-like and BRCA1 mutant phenotypes distinct from ErbB2-overexpressing breast cancers. Yet, EGFR is substantially weaker compared with ErbB2 in promoting the oncogenic transformation of non-tumorigenic human mammary epithelial cells (human MEC), suggesting a role for cooperating oncogenes. Here, we have modeled the co-overexpression of EGFR and a biologically and clinically relevant potential modifier c-Src in two distinct immortal but nontumorigenic human MECs. Using a combination of morphologic analysis and confocal imaging of polarity markers in three-dimensional Matrigel culture together with functional analyses of early oncogenic traits, we show for the first time that EGFR and c-Src co-overexpression but not EGFR or c-Src overexpression alone unleashes an oncogenic signaling program that leads to hyperproliferation and loss of polarity in three-dimensional acinar cultures, marked enhancement of migratory and invasive behavior, and anchorage-independent growth. Our results establish that EGFR overexpression in an appropriate context (modeled here using c-Src overexpression) can initiate oncogenic transformation of nontumorigenic human MECs and provide a suitable in vitro model to interrogate human breast cancer-relevant oncogenic signaling pathways initiated by overexpressed EGFR and to identify modifiers of EGFR-mediated breast oncogenesis.
AB - Epidermal growth factor receptor (EGFR), a member of the ErbB family of receptor tyrosine kinases, is overexpressed in as many as 60% cases of breast and other cancers. EGFR overexpression is a characteristic of highly aggressive molecular subtypes of breast cancer with basal-like and BRCA1 mutant phenotypes distinct from ErbB2-overexpressing breast cancers. Yet, EGFR is substantially weaker compared with ErbB2 in promoting the oncogenic transformation of non-tumorigenic human mammary epithelial cells (human MEC), suggesting a role for cooperating oncogenes. Here, we have modeled the co-overexpression of EGFR and a biologically and clinically relevant potential modifier c-Src in two distinct immortal but nontumorigenic human MECs. Using a combination of morphologic analysis and confocal imaging of polarity markers in three-dimensional Matrigel culture together with functional analyses of early oncogenic traits, we show for the first time that EGFR and c-Src co-overexpression but not EGFR or c-Src overexpression alone unleashes an oncogenic signaling program that leads to hyperproliferation and loss of polarity in three-dimensional acinar cultures, marked enhancement of migratory and invasive behavior, and anchorage-independent growth. Our results establish that EGFR overexpression in an appropriate context (modeled here using c-Src overexpression) can initiate oncogenic transformation of nontumorigenic human MECs and provide a suitable in vitro model to interrogate human breast cancer-relevant oncogenic signaling pathways initiated by overexpressed EGFR and to identify modifiers of EGFR-mediated breast oncogenesis.
UR - http://www.scopus.com/inward/record.url?scp=34249325876&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34249325876&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-06-2580
DO - 10.1158/0008-5472.CAN-06-2580
M3 - Article
C2 - 17483327
AN - SCOPUS:34249325876
SN - 0008-5472
VL - 67
SP - 4164
EP - 4172
JO - Cancer Research
JF - Cancer Research
IS - 9
ER -